Journey Medical Co. (NASDAQ:DERM - Free Report) - Roth Capital cut their Q1 2025 earnings estimates for Journey Medical in a research report issued on Thursday, March 27th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of ($0.19) per share for the quarter, down from their previous forecast of ($0.05). The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical's Q2 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.05 EPS, FY2026 earnings at $2.18 EPS, FY2027 earnings at $3.32 EPS and FY2028 earnings at $5.18 EPS.
Journey Medical (NASDAQ:DERM - Get Free Report) last announced its quarterly earnings results on Wednesday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.30. The firm had revenue of $14.30 million during the quarter, compared to the consensus estimate of $14.21 million. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%.
Separately, Alliance Global Partners reiterated a "buy" rating on shares of Journey Medical in a research note on Thursday, March 27th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $9.67.
Get Our Latest Report on Journey Medical
Journey Medical Stock Up 3.5 %
Shares of NASDAQ:DERM traded up $0.21 during mid-day trading on Monday, hitting $6.18. 40,590 shares of the company traded hands, compared to its average volume of 85,104. The firm's 50 day simple moving average is $5.18 and its 200 day simple moving average is $5.18. The firm has a market cap of $129.10 million, a P/E ratio of -6.57 and a beta of 0.97. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. Journey Medical has a 52-week low of $3.20 and a 52-week high of $6.89.
Hedge Funds Weigh In On Journey Medical
Hedge funds have recently bought and sold shares of the company. Tang Capital Management LLC bought a new position in Journey Medical during the 4th quarter worth approximately $6,747,000. Cetera Investment Advisers lifted its stake in Journey Medical by 21.8% during the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock worth $54,000 after purchasing an additional 2,478 shares during the last quarter. Citadel Advisors LLC bought a new position in Journey Medical during the fourth quarter worth $174,000. Kovitz Investment Group Partners LLC increased its stake in Journey Medical by 112.9% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company's stock valued at $97,000 after purchasing an additional 13,105 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Journey Medical during the fourth quarter worth $80,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Journey Medical
In other news, CEO Claude Maraoui sold 14,905 shares of the business's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.01, for a total value of $74,674.05. Following the completion of the sale, the chief executive officer now owns 2,052,418 shares of the company's stock, valued at approximately $10,282,614.18. The trade was a 0.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 105,831 shares of company stock worth $536,622 in the last 90 days. 13.16% of the stock is owned by corporate insiders.
About Journey Medical
(
Get Free Report)
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Featured Stories
Before you consider Journey Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.
While Journey Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
